Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

医学 索拉非尼 肝细胞癌 卡波扎尼布 内科学 实体瘤疗效评价标准 肿瘤科 阿替唑单抗 肝功能 癌症 临床研究阶段 临床试验 胃肠病学 外科 彭布罗利珠单抗 免疫疗法
作者
Robin Kate Kelley,Lorenza Rimassa,Ann‐Lii Cheng,Ahmed O. Kaseb,Shukui Qin,Andrew X. Zhu,Stephen L. Chan,Tamar Melkadze,Wattana Sukeepaisarnjaroen,В. В. Бредер,Gontran Verset,Edward Gane,Ivan Borbath,Jose David Gomez Rangel,Baek‐Yeol Ryoo,Tamta Makharadze,Philippe Merle,Fawzi Benzaghou,Kamalika Banerjee,Saswati Hazra,Jonathan Fawcett,Thomas Yau
出处
期刊:Lancet Oncology [Elsevier]
卷期号:23 (8): 995-1008 被引量:331
标识
DOI:10.1016/s1470-2045(22)00326-6
摘要

BackgroundCabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma.MethodsCOSMIC-312 is an open-label, randomised, phase 3 trial that enrolled patients aged 18 years or older with advanced hepatocellular carcinoma not amenable to curative or locoregional therapy and previously untreated with systemic anticancer therapy at 178 centres in 32 countries. Patients with fibrolamellar carcinoma, sarcomatoid hepatocellular carcinoma, or combined hepatocellular cholangiocarcinoma were not eligible. Tumours involving major blood vessels, including the main portal vein, were permitted. Patients were required to have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), Barcelona Clinic Liver Cancer stage B or C disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, adequate organ and marrow function, and Child-Pugh class A. Previous resection, tumour ablation, radiotherapy, or arterial chemotherapy was allowed if more than 28 days before randomisation. Patients were randomly assigned (2:1:1) via a web-based interactive response system to cabozantinib 40 mg orally once daily plus atezolizumab 1200 mg intravenously every 3 weeks, sorafenib 400 mg orally twice daily, or single-agent cabozantinib 60 mg orally once daily. Randomisation was stratified by disease aetiology, geographical region, and presence of extrahepatic disease or macrovascular invasion. Dual primary endpoints were progression-free survival per RECIST 1.1 as assessed by a blinded independent radiology committee in the first 372 patients randomly assigned to the combination treatment of cabozantinib plus atezolizumab or sorafenib (progression-free survival intention-to-treat [ITT] population), and overall survival in all patients randomly assigned to cabozantinib plus atezolizumab or sorafenib (ITT population). Final progression-free survival and concurrent interim overall survival analyses are presented. This trial is registered with ClinicalTrials.gov, NCT03755791.FindingsAnalyses at data cut-off (March 8, 2021) included the first 837 patients randomly assigned between Dec 7, 2018, and Aug 27, 2020, to combination treatment of cabozantinib plus atezolizumab (n=432), sorafenib (n=217), or single-agent cabozantinib (n=188). Median follow-up was 15·8 months (IQR 14·5–17·2) in the progression-free survival ITT population and 13·3 months (10·5–16·0) in the ITT population. Median progression-free survival was 6·8 months (99% CI 5·6–8·3) in the combination treatment group versus 4·2 months (2·8–7·0) in the sorafenib group (hazard ratio [HR] 0·63, 99% CI 0·44–0·91, p=0·0012). Median overall survival (interim analysis) was 15·4 months (96% CI 13·7–17·7) in the combination treatment group versus 15·5 months (12·1–not estimable) in the sorafenib group (HR 0·90, 96% CI 0·69–1·18; p=0·44). The most common grade 3 or 4 adverse events were alanine aminotransferase increase (38 [9%] of 429 patients in the combination treatment group vs six [3%] of 207 in the sorafenib group vs 12 [6%] of 188 in the single-agent cabozantinib group), hypertension (37 [9%] vs 17 [8%] vs 23 [12%]), aspartate aminotransferase increase (37 [9%] vs eight [4%] vs 18 [10%]), and palmar-plantar erythrodysaesthesia (35 [8%] vs 17 [8%] vs 16 [9%]); serious treatment-related adverse events occurred in 78 (18%) patients in the combination treatment group, 16 (8%) patients in the sorafenib group, and 24 (13%) in the single-agent cabozantinib group. Treatment-related grade 5 events occurred in six (1%) patients in the combination treatment group (encephalopathy, hepatic failure, drug-induced liver injury, oesophageal varices haemorrhage, multiple organ dysfunction syndrome, and tumour lysis syndrome), one (<1%) patient in the sorafenib group (general physical health deterioration), and one (<1%) patient in the single-agent cabozantinib group (gastrointestinal haemorrhage).InterpretationCabozantinib plus atezolizumab might be a treatment option for select patients with advanced hepatocellular carcinoma, but additional studies are needed.FundingExelixis and Ipsen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英姑应助霸气的梦露采纳,获得10
1秒前
蘑菇完成签到,获得积分10
1秒前
1秒前
Wind发布了新的文献求助10
1秒前
纪鹏飞完成签到,获得积分10
2秒前
crookshanks88发布了新的文献求助10
2秒前
星辰大海应助李李李采纳,获得10
3秒前
不配.应助暴躁的信封采纳,获得10
3秒前
Xx发布了新的文献求助10
4秒前
赫连紫发布了新的文献求助10
4秒前
rosalieshi应助紧张的沧海采纳,获得30
5秒前
xinanan发布了新的文献求助10
5秒前
6秒前
芙瑞完成签到 ,获得积分10
7秒前
Ava应助Wind采纳,获得10
7秒前
星星发布了新的文献求助10
7秒前
善良寒风完成签到,获得积分10
8秒前
李健的小迷弟应助IAMXC采纳,获得10
8秒前
Lan完成签到 ,获得积分10
8秒前
10秒前
10秒前
Akim应助MARS采纳,获得10
10秒前
14秒前
在水一方应助Xx采纳,获得10
14秒前
明亮随阴发布了新的文献求助10
16秒前
23完成签到,获得积分10
16秒前
爆裂奶綠关注了科研通微信公众号
16秒前
16秒前
Cataphyll完成签到 ,获得积分10
18秒前
18秒前
yuqian发布了新的文献求助10
20秒前
20秒前
21秒前
xinanan完成签到,获得积分10
22秒前
22秒前
MARS发布了新的文献求助10
22秒前
itachi完成签到,获得积分10
23秒前
23秒前
成就的书包完成签到,获得积分10
25秒前
ssl完成签到 ,获得积分10
27秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
XAFS for Everyone 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3143695
求助须知:如何正确求助?哪些是违规求助? 2795199
关于积分的说明 7813564
捐赠科研通 2451202
什么是DOI,文献DOI怎么找? 1304353
科研通“疑难数据库(出版商)”最低求助积分说明 627221
版权声明 601393